AccutarBio is a series c plus startup. 2 investors tracked. Status: possibledead.
AccutarBio is a startup founded in 2020 based in the United States. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
AccutarBio is a clinical-stage biotech company leveraging artificial intelligence to accelerate drug discovery. It uses a hybrid approach of computational drug design followed by wet-lab validation to reduce time and costs in traditional drug discovery efforts, focusing on targeted protein degradation therapies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.